Is Retatrutide Available in Canada? Yes — retatrutide is available in Canada as a research peptide. As it completes Phase 3 clinical trials globally, it is accessible as a research compound for qualified investigators and laboratory use. For a detailed…
Retatrutide Dosing: A Research Protocol Reference This guide compiles dosing information, reconstitution procedures, and storage guidelines for retatrutide based on published clinical trial literature and standard peptide handling protocols. It is intended as a reference for researchers working with retatrutide…
Retatrutide Clinical Trials: Where We Stand in 2026 Retatrutide (LY3437943) has emerged as one of the most closely watched peptide compounds in metabolic research. Following landmark Phase 2 results published in The New England Journal of Medicine, the compound has…
Comparing Retatrutide, Tirzepatide, and Semaglutide The metabolic peptide research landscape has evolved rapidly with the development of multi-receptor agonists. While semaglutide established the foundation as a single GLP-1 receptor agonist, tirzepatide advanced the field with dual GLP-1/GIP agonism, and now…
What Is Retatrutide? Retatrutide (LY3437943) is a novel triple-agonist peptide developed by Eli Lilly that simultaneously activates three incretin-related receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple mechanism distinguishes retatrutide from dual-agonist compounds like tirzepatide…
Welcome to Great Northern Peptides. Canada’s Newest Source for Quality Peptides We’re thrilled to announce the official launch of Great Northern Peptides, your Canadian‑based destination for high quality, trusted peptide products. This is more than just a new website —…
